The Inhibitory Effect of Conjugated and Polyunsaturated Fatty Acids on the Growth of Human Cancer Cell Lines

arachidonic acidconjugated fatty acidcytotoxicitydocosahexaenoic acideicosapentaenoic acidhuman cancer cerllpolyunsaturated fatty aci

Iron Emission Lines on the Galactic Ridge Observed with Suzaku

In order to elucidate origin of the Galactic Ridge X-ray Emission, we analyzed Suzaku data taken at various regions along the Galactic plane and studied their Fe-K emission line features. Suzaku resolved the Fe line complex into three narrow lines at ~6.4 keV,~6.7 keV and ~6.97 keV, which are K-lines from neutral (or low-ionized), He-like, and H-like iron ions, respectively. The 6.7 keV line is clearly seen in all the observed regions and its longitudinal distribution is consistent with that determined from previous observations. The 6.4 keV emission line was also found in various Galactic plane regions (b~0). Differences in flux ratios of the 6.4 keV/6.7 keV and 6.97 keV/6.7 keV lines between the Galactic plane and the Galactic center regions are studied and its implication is discussed.Comment: Accepted for publication in PASJ Suzaku 3rd special issu

閉塞型睡眠時無呼吸症候群患者における早朝の高分子量フォンウィルブランド因子減少は無呼吸の重症度を反映する

Plasma von Willebrand factor (VWF), produced in and released from vascular endothelial cells by various stimuli including hypoxia, induces platelet aggregation under high shear stress and plays dual pivotal roles in haemostasis and thrombosis within arterioles, which are regulated by the size of vWF multimers (VWFMs). Patients with obstructive sleep apnoea (OSA) have increased risk of thrombotic cardiovascular events, but the pathogenesis is unclear. We examined the relationship between VWF and OSA by measuring VWF antigen (VWF:Ag), VWFMs, VWF collagen binding activity (VWF:CB) and a disintegrin-like, metalloproteinase, and thrombospiondin type 1 motifs 13. A total of 58 OSA patients were enrolled. Blood samples were collected before sleep, after sleep, and after one night of nasal continuous positive airway pressure therapy. Based on VWFM analysis, OSA patients were classified into three groups; consistently normal VWFMs (group 1, n=29), increased high molecular weight (HMW)-VWFMs at 06:00 h (group 2, n=18), and decreased or absent HMW-VWFMs at 06:00 h (group 3, n=11). Patients in group 3 had significantly worse apnoea/hypopnoea index; VWF:CB followed a similar pattern. We observed a significant decrease in platelet count between 21:00 h and 06:00 h in OSA patients, potentially associated with reduced larger VWFMs together with decreased VWF:Ag levels. Severe OSA may contribute to an arterial pro-thrombotic state.博士（医学）・乙第1294号・平成24年5月28日Copyright © 2012 by the European Respiratory Societ

On a system of qq-partial differential equations with applications to qq-series

Using the theory of functions of several variables and $q$-calculus, we prove an expansion theorem for the analytic function in several variables which satisfies a system of $q$-partial differential equations. Some curious applications of this expansion theorem to $q$-series are discussed. In particular, an extension of Andrews' transformation formula for the $q$-Lauricella function is given.Comment: 15 pages, accepted for the proceedings of the Alladi 60th birthday conferenc

Use of a Caco-2 permeability assay to evaluate the effects of several Kampo medicines on the drug transporter P-glycoprotein

In modern medical care in which Kampo and Western drugs are often combined, it is extremely important to clarify drug–drug interaction (DDI) to ensure safety and efficacy. However, there is little evidence of DDI in Kampo medicines. Therefore, as part of our studies to clarify the DDI risk for Kampo medicines, we evaluated the effects of five Kampo medicines [yokukansan (YKS), rikkunshito (RKT), shakuyakukanzoto (SKT), hangeshashinto (HST), and goshajinkigan (GJG)] that are widely used in Japan, on drug transporter P-glycoprotein (P-gp) using a Caco-2 permeability assay. These Kampo medicines inhibited the P-gp transport of digoxin through a Caco-2 cell monolayer. The IC50 values were 1.94–10.80 mg/ml. Of the five Kampo medicines, YKS showed the strongest inhibition (IC50 = 1.94 mg/ml), which was attributed to Uncariae Uncis Cum Ramulus. Unfortunately, we could not find the active ingredients responsible for its action. Finally, the Igut/IC50 values for the five Kampo medicines were calculated, and the DDI risk was objectively evaluated according to the criteria in the DDI guidance issued by the Japanese Ministry of Health, Labor, and Welfare and the US Food and Drug Administration. The Igut/IC50 values for the five Kampo medicines were ≤3.4. As these values were <10, they were evaluated as having a weak P-gp inhibitory effect that does not require further verification in humans, suggesting that the DDI risk due to P-gp inhibition for these Kampo medicines is low. The results should provide useful clinical information on the safety and efficacy of the combined use of Kampo and Western medicines